| Strategy | Mean costs (£) | Mean QALYs | ICER (£) | Probability of being cost-effective for threshold at: | ||
| £20 000 | £30 000 | |||||
| Lifetime analysis | ||||||
| CHADS2 = 0 | RFCA | 25 240 | 12.37 | 7763 | 0.983 | 0.996 |
| AADs | 14 415 | 10.98 | – | |||
| CHADS2 = 1 | RFCA | 26 027 | 12.14 | 7780 | 0.981 | 0.996 |
| AADs | 15 367 | 10.77 | – | |||
| CHADS2 = 2 | RFCA | 26 987 | 11.87 | 7765 | 0.986 | 0.999 |
| AADs | 16 517 | 10.52 | – | |||
| CHADS2 = 3 | RFCA | 28 343 | 11.49 | 7910 | 0.992 | 1.000 |
| AADs | 18 107 | 10.19 | – | |||
| 5-year analysis | ||||||
| CHADS2 = 0 | RFCA | 25 251 | 11.35 | 27 745 | 0.091 | 0.577 |
| AADs | 14 429 | 10.96 | – | |||
| CHADS2 = 1 | RFCA | 26 016 | 11.18 | 25 510 | 0.165 | 0.686 |
| AADs | 15 352 | 10.76 | – | |||
| CHADS2 = 2 | RFCA | 26 972 | 10.97 | 23 202 | 0.265 | 0.786 |
| AADs | 16 499 | 10.52 | – | |||
| CHADS2 = 3 | RFCA | 28 366 | 10.67 | 20 831 | 0.418 | 0.881 |
| AADs | 18 133 | 10.18 | – | |||
AAD, anti-arrhythmic drug; CHADS2, congestive heart failure, hypertension, age 75, diabetes mellitus, and prior stroke; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; RFCA, radiofrequency catheter ablation.